AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37442883 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 173
Study 37442917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 91
Study 37442955 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child ADHD screening protocol during annual well-child visits in pediatric primary care clinics.
Number of subjects: 0
Study 37442955 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder group meetings to gather feedback on implementation challenges.
Number of subjects: 0
Study 37442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored model of Family Psychoeducation (KUPAA)
Number of subjects: 66
Study 37443016 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-upright position (30 to 45 degrees incline)
Number of subjects: 35
Study 37443016 — intervention group
Group type: COMPARATOR
Intervention: Control group (zero degrees from horizontal)
Number of subjects: 35
Study 37443044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy including mHealth outreach, care coordination, and community advisory boards
Number of subjects: 300
Study 37443044 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy
Number of subjects: 300
Study 37443047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary rapid nucleic acid test (Abbott ID NOW STREP A2)
Number of subjects: 800
Study 37443047 — intervention group
Group type: COMPARATOR
Intervention: Pharyngeal rapid antigen detection test (EXACTO PRO STREPTATEST)
Number of subjects: 800
Study 37443061 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative light induced fluorescence (QLF) technology
Number of subjects: 0
Study 37443083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ringer's Lactate (RL)
Number of subjects: 52
Study 37443083 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 52
Study 37443130 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 414
Study 37443130 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 414
Study 37443348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelareorep and pembrolizumab (iv pelareorep induction with pembrolizumab every 21-days)
Number of subjects: 12
Study 37443414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse navigation program-based nursing care (three home visits, four phone calls, five text messages)
Number of subjects: 64
Study 37443414 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care during delivery and postpartum period
Number of subjects: 64
Study 37443452 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH-TPOAb [-] group (levothyroxine treatment)
Number of subjects: 171
Study 37443452 — intervention group
Group type: COMPARATOR
Intervention: SCH-TPOAb [+] group (control)
Number of subjects: 171
Study 37443809 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CRP protein levels of ≥5 mg/L
Number of subjects: 0
Study 37443809 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs1130864
Number of subjects: 0
Study 37444406 — intervention group
Group type: EXPERIMENTAL
Intervention: Current MDS treatments
Number of subjects: 75
Study 37444551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg, po BID)
Number of subjects: 151
Study 37444551 — intervention group
Group type: COMPARATOR
Intervention: Interruption of Sorafenib treatment
Number of subjects: 151
Study 37444551 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of Sorafenib treatment
Number of subjects: 151
Study 37444634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation treatment for brain regions with Cho/NAA ≥ 2x normal
Number of subjects: 0
Study 37444757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility-sparing surgery
Number of subjects: 86
Study 37444757 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive surgical staging
Number of subjects: 86
Study 37444757 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 86
Study 37444757 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of Ca-125
Number of subjects: 86
Study 37444757 — intervention group
Group type: EXPERIMENTAL
Intervention: Serous BOT diagnosis
Number of subjects: 86
Study 37444782 — intervention group
Group type: EXPERIMENTAL
Intervention: TEPOH (multicomponent intervention including an introductory session, three educational sessions, and a debriefing session)
Number of subjects: 81
Study 37444782 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 81
Study 37445292 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid mixture with tricarboxylic acid cycle intermediates (PD-E07), N = 10
Number of subjects: 40
Study 37445292 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR), N = 10
Number of subjects: 40
Study 37446173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitisinone treatment
Number of subjects: 0
Study 37448202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition + exercise intervention (bi-weekly nutrition counselling, high dairy protein diet, walking goal of 10,000 steps/day, plus usual prenatal care)
Number of subjects: 100
Study 37448202 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care (UPC) alone
Number of subjects: 100
Study 37448353 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (1.0 to 1.5 g orally)
Number of subjects: 0
Study 37448694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 300 mg daily for six months
Number of subjects: 59
Study 37448694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 37448803 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 14
Study 37448803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 37449421 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishing stroke registers in two large referral hospitals in Tanzania
Number of subjects: 0
Study 37449423 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37449424 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD alone
Number of subjects: 12856
Study 37449424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAD and stroke
Number of subjects: 12856
Study 37449424 — intervention group
Group type: COMPARATOR
Intervention: Stroke alone
Number of subjects: 12856
Study 37449426 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID)
Number of subjects: 10
Study 37449560 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution (STR) ≥50%
Number of subjects: 5966
Study 37449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (STR)
Number of subjects: 5966
Study 37449560 — intervention group
Group type: COMPARATOR
Intervention: STR <50%
Number of subjects: 5966
Study 37449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful STR and TIMI 3 flow
Number of subjects: 5966
Study 37449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Either STR or TIMI flow reduced
Number of subjects: 5966
Study 37449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both STR and TIMI flow abnormal
Number of subjects: 5966
Study 37449567 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 months of Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1326
Study 37449567 — intervention group
Group type: COMPARATOR
Intervention: 12 months of Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1326
Study 37449568 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2934
Study 37449568 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2934
Study 37449573 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve modulation (SNM) with ropivacaine
Number of subjects: 15
Study 37449658 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneously on day 1 of every 4-week cycle, with loading doses of 120 mg on days 8 and 15)
Number of subjects: 3
Study 37449658 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 3
Study 37449715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic cancer survivors with LRTIs
Number of subjects: 83
Study 37449715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel and urinary LRTIs
Number of subjects: 83
Study 37449715 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger survivors, gynecological cancer survivors, or those who received external and internal radiation or additional chemotherapy
Number of subjects: 83
Study 37449715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health dimensions
Number of subjects: 83
Study 37449716 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (97/103 mg twice daily)
Number of subjects: 480
Study 37449716 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 480
Study 37449768 — intervention group
Group type: EXPERIMENTAL
Intervention: EMM + $1 per day for perfect medication adherence for 3 months (maximum $84) followed by 1 month of EMM only
Number of subjects: 52
Study 37449768 — intervention group
Group type: COMPARATOR
Intervention: Control group: EMM with App reminders/feedback for 4 months
Number of subjects: 52
Study 37449908 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-212 (ImmTOR 0.15 mg/kg and pegadricase 0.2 mg/kg)
Number of subjects: 0
Study 37449908 — intervention group
Group type: COMPARATOR
Intervention: Pegloticase (8 mg)
Number of subjects: 0
Study 37449908 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-212 (ImmTOR and pegadricase)
Number of subjects: 0
Study 37450086 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH-CHECK
Number of subjects: 253
Study 37450196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart (faster aspart)
Number of subjects: 178
Study 37450201 — intervention group
Group type: EXPERIMENTAL
Intervention: cTTP-PEQ
Number of subjects: 36
Study 37450303 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 135
Study 37450351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 0
Study 37450351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) + SMAC mimetics
Number of subjects: 0
Study 37450613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 h/1 h algorithm
Number of subjects: 5497
Study 37450613 — intervention group
Group type: COMPARATOR
Intervention: 0 h/3 h protocol
Number of subjects: 5497
Study 37450613 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (grey zone) of 0 h/1 h algorithm
Number of subjects: 5497
Study 37450613 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of troponin <5 ng/L
Number of subjects: 5497
Study 37450613 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with troponin levels
Number of subjects: 5497
Study 37450670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pudendal nerve block with liposomal bupivacaine
Number of subjects: 83
Study 37450670 — intervention group
Group type: COMPARATOR
Intervention: No block
Number of subjects: 83
Study 37450869 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocap (bioresorbable nerve capping device)
Number of subjects: 73
Study 37450935 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Doxycycline therapy
Number of subjects: 0
Study 37450935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37451283 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture and color enhancement imaging (TXI)
Number of subjects: 747
Study 37451283 — intervention group
Group type: COMPARATOR
Intervention: High definition white-light imaging (WLI)
Number of subjects: 747
Study 37451291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg intravenously every 6 weeks for up to 18 cycles (2 years) plus lenvatinib 20 mg orally once daily.
Number of subjects: 158
Study 37451291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 158
Study 37451295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks for 1 year
Number of subjects: 179
Study 37451295 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 179
Study 37451297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenacapavir (600 mg, days 1 and 2; 300 mg, day 8) followed by subcutaneous lenacapavir 927 mg every 26 weeks
Number of subjects: 72
Study 37451297 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised background regimen concurrent with lenacapavir (oral to subcutaneous)
Number of subjects: 72
Study 37451297 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by lenacapavir (2-week oral lead-in then subcutaneous)
Number of subjects: 72
Study 37451339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use (SU) ancillaries
Number of subjects: 20
Study 37451352 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate uncoupling (Ees/Ea 0.8-1.29)
Number of subjects: 53
Study 37451352 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe uncoupling (Ees/Ea < 0.8)
Number of subjects: 53
Study 37451352 — intervention group
Group type: COMPARATOR
Intervention: Low hemodynamic risk
Number of subjects: 53
Study 37451352 — intervention group
Group type: COMPARATOR
Intervention: Intermediate hemodynamic risk
Number of subjects: 53
Study 37451355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist interpretation of point-of-care handheld 1L ECGs
Number of subjects: 15
Study 37451695 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil counts in patients with PD
Number of subjects: 376
Study 37451695 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher neutrophil levels in patients with PD
Number of subjects: 376
Study 37451695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte count and NLR in patients with PD
Number of subjects: 376
Study 37451695 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count in patients with PD
Number of subjects: 376
Study 37451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measured by three-level EuroQol five-dimension and visual analogy scale at admission, 1 month, 6 months, 12 months, and 10 years follow-up.
Number of subjects: 14899
Study 37451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications and medication adherence.
Number of subjects: 14899
Study 37451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Information about Medicines Scale and illness perceptions.
Number of subjects: 14899
Study 37451698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal and non-fatal outcomes following MI.
Number of subjects: 14899
Study 37451701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (maximum 5 mg)
Number of subjects: 11
Study 37451701 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (maximum 400 mg)
Number of subjects: 11
Study 37451701 — intervention group
Group type: COMPARATOR
Intervention: Baseline (post-run-in pooled)
Number of subjects: 11
Study 37451701 — intervention group
Group type: EXPERIMENTAL
Intervention: Other non-invasive cardiopulmonary measures
Number of subjects: 11
Study 37451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional care concept developed through mixed-methods design including literature review, qualitative inquiries, and structured workshops.
Number of subjects: 100
Study 37451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on collaboration completed by 100 individuals from each group involved in home care.
Number of subjects: 100
Study 37451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoprofessional focus groups (n=9) of registered nurses, general practitioners, and therapists discussing current practices.
Number of subjects: 100
Study 37451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice cases (n=8) analyzed through case-based qualitative content analysis.
Number of subjects: 100
Study 37451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed focus groups (n=4) with findings from WP2 discussed.
Number of subjects: 100
Study 37451717 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and motivational mobile health (mHealth) intervention
Number of subjects: 80000
Study 37451717 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80000
Study 37451727 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP) consisting of four sessions (once per week) of manual therapy applied to temporomandibular structures.
Number of subjects: 120
Study 37451728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary combined Exercise and Nutrition Intervention (MENTORS)
Number of subjects: 168
Study 37451728 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (part of MENTORS)
Number of subjects: 168
Study 37451728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (part of MENTORS)
Number of subjects: 168
Study 37451734 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training (LT) paired with transcutaneous spinal cord stimulation (TSCS) for 12 weeks
Number of subjects: 12
Study 37451734 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training (LT) paired with sham stimulation for 12 weeks
Number of subjects: 12
Study 37451735 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (720 µg/day) and vitamin D3 (25 µg/day) for 2 years
Number of subjects: 400
Study 37451735 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (no active treatment) for 2 years
Number of subjects: 400
Study 37451738 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-to-suppression intervention (D2S) providing surveillance-based reports and capacity-building assistance.
Number of subjects: 1619
Study 37451738 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed implementation of the intervention).
Number of subjects: 1619
Study 37451740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention (4 weeks, 1 weekly session of ~1 to 1.5 hours)
Number of subjects: 11
Study 37451740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Number of subjects: 11
Study 37451840 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic oxygen control (A-FiO2)
Number of subjects: 60
Study 37451840 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 60
Study 37451877 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumos-v1 vaccine (tetravalent mosaic influenza nanoparticle vaccine)
Number of subjects: 0
Study 37451930 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, carboplatin, pemetrexed, and bevacizumab
Number of subjects: 117
Study 37451930 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin, pemetrexed, and bevacizumab
Number of subjects: 117
Study 37451932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Care
Number of subjects: 159
Study 37451932 — intervention group
Group type: COMPARATOR
Intervention: Serial Care
Number of subjects: 159
Study 37452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) alone
Number of subjects: 517
Study 37452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors (TKIs)
Number of subjects: 517
Study 37452107 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 517
Study 37452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (either ICIs alone or with TKIs)
Number of subjects: 517
Study 37452107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) alone or with TKIs
Number of subjects: 517
Study 37452140 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 90
Study 37452140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90
Study 37452140 — intervention group
Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 90
Study 37452151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 0
Study 37452151 — intervention group
Group type: COMPARATOR
Intervention: Control (DSE)
Number of subjects: 0
Study 37452167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-textured foods
Number of subjects: 18
Study 37452167 — intervention group
Group type: COMPARATOR
Intervention: (Ultra)processed soft condition
Number of subjects: 18
Study 37452174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + Rilpivirine long-acting (CAB+RPV) administered every 2 months (Q2M)
Number of subjects: 0
Study 37452174 — intervention group
Group type: COMPARATOR
Intervention: Daily oral single-tablet regimens (STRs)
Number of subjects: 0
Study 37452196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 728
Study 37452196 — intervention group
Group type: COMPARATOR
Intervention: Ventilation
Number of subjects: 728
Study 37452279 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (NMB)
Number of subjects: 10
Study 37452279 — intervention group
Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 10
Study 37452279 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 10
Study 37452281 — intervention group
Group type: EXPERIMENTAL
Intervention: TaU + MIND (mindfulness-based intervention added to treatment as usual)
Number of subjects: 177
Study 37452281 — intervention group
Group type: COMPARATOR
Intervention: TaU (treatment as usual)
Number of subjects: 177
Study 37452281 — intervention group
Group type: EXPERIMENTAL
Intervention: TaU + MIND
Number of subjects: 177
Study 37452281 — intervention group
Group type: COMPARATOR
Intervention: TaU
Number of subjects: 177
Study 37452330 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5% three times a day
Number of subjects: 101
Study 37452330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 37452341 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (S-DHA)
Number of subjects: 40
Study 37452341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40